Compare ABCL & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCL | NRK |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 888.1M |
| IPO Year | 2020 | N/A |
| Metric | ABCL | NRK |
|---|---|---|
| Price | $3.98 | $10.17 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 187.3K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,325,000.00 | N/A |
| Revenue This Year | $25.45 | N/A |
| Revenue Next Year | $10.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.17 | N/A |
| 52 Week Low | $1.89 | $8.95 |
| 52 Week High | $6.52 | $11.09 |
| Indicator | ABCL | NRK |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 53.29 |
| Support Level | $3.92 | $10.11 |
| Resistance Level | $4.25 | $10.19 |
| Average True Range (ATR) | 0.31 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.94 | 38.89 |
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.